Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression

Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy. However, the mechanisms by which constitutively activated KRAS (KRAS(G12V)) impairs effector mechanisms of EGFR-Abs are incompletely un...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Derer, Stefanie, Berger, Sven, Schlaeth, Martin, Schneider-Merck, Tanja, Klausz, Katja, Lohse, Stefan, Overdijk, Marije B, Dechant, Michael, Kellner, Christian, Nagelmeier, Iris, Scheel, Andreas H, Lammerts van Bueren, Jeroen J, van de Winkel, Jan GJ, Parren, Paul WHI, Peipp, Matthias, Valerius, Thomas
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press Inc. 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3323897/
https://ncbi.nlm.nih.gov/pubmed/22496619
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars